°å¡¡²½¡¡³Ø¡¡¹Ö¡¡ºÂ

¡Ô¸¦µæ³µÍסÕ

£±¡ËÄˤߤÎÅÁ㵡¹½
¡¡ËÜÍèÄˤߤòͶȯ¤·¤Ê¤¤¿¨³Ð»É·ã¤¬¤É¤ÎÍͤʿÀ·Ð²óÏ©¤äÀ¸Âΰø»Ò¤ò²ð¤·¤ÆÄˤߡʥ¢¥í¥Ç¥£¥Ë¥¢¡Ë¤òͶȯ¤¹¤ë¤Î¤«¡¢Ä˳вáÉÒÈ¿±þ¤ËÈæ¤·¤Æ¡¢¤½¤Îȯ¸½µ¡½ø¤Ï̤¤À¤ËÉÔÌÀ¤ÊÅÀ¤¬Â¿¤¤¡£Ä˳ФÎÅÁ㤬°ì¼¡µá¿´À­Àþ°Ý¤ÎÆþÎÏ¡¢ÀÔ¿ñ¸å³Ñ¤Î¿À·ÐºÙ˦¡¢Áع½Â¤¤Ç¤É¤Î¤è¤¦¤ËÀ©¸æ¤µ¤ì¤Æ¤¤¤ë¤Î¤«¡¢¤Ê¤¼¿¨³Ð¤¬Ä˳ФȤ·¤Æ¸íǧ¤µ¤ì¤ë¤Î¤«¤È¤¤¤¦½ÅÍפ«¤Ä´ðËÜŪ¤ÊÌäÂê¤ò¿À·Ð¤Î²ÄÁºÀ­¤Ë¾ÇÅÀ¤ò¤¢¤Æ¤Æ¸¦µæ¤ò¿Ê¤á¤Æ¤¤¤ë¡£Åö¶µ¼¼¤Ë¤ª¤¤¤Æ¥Î¥Ã¥¯¥¢¥¦¥È(KO)¥Þ¥¦¥¹¤òÍѤ¤¤¿¹ÔưÌôÍý¼Â¸³¤«¤é¡¢¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥ó (PG) ¡¢¥ª¥Ô¥ª¥¤¥É¡Ê¥Î¥·¥»¥×¥Á¥ó¡ÊNoc/OFQ¡Ë¡¢¥Î¥·¥¹¥¿¥Á¥ó¡ÊNST¡Ë¡Ë¡¢¥°¥ë¥¿¥ß¥ó»À¤ä°ì»À²½ÃâÁÇ (NO) ¤¬¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´ØÍ¿¤¹¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤Æ¤­¤¿¡£º£Ç¯Å٤ϡ¢¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´ØÍ¿¤¹¤ë¿·µ¬°äÅÁ»Ò¤Î¥¯¥í¡¼¥Ë¥ó¥°¡¢°äÅÁ»Ò¤Îȯ¸½ÊѲ½¤Ëȼ¤¦ÄˤߤÎȯÀ¸µ¡¹½¡¢ÀÔ¿ñ¥¹¥é¥¤¥¹¤òÍѤ¤¤¿¿À·Ð²óÏ©Ì֤ζõ´ÖŪ¡¢»þ´ÖŪ¥¤¥á¡¼¥¸¥ó¥°¡¢È¯¸÷ÃÁÇò¼Á´Ö¤Ç¥¨¥Í¥ë¥®¡¼°Üư¡ÊBRET¡¢Bioluminescence Resonance Energy Transfer )¤òÍøÍѤ·¤¿Noc/OFQ¤ÈNST¤Î»ºÀ¸Ä´Àᵡ¹½¤Ë´Ø¤¹¤ë¸¦µæ¤ò¹Ô¤Ã¤¿¡£

i)¡¡¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´ØÍ¿¤¹¤ëÆÃ°ÛŪ°äÅÁ»Ò¤ÎñΥ
¡¡²æ¡¹¤ÏPGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤¬¥«¥×¥µ¥¤¥·¥óÈó´¶¼õÀ­¤ÎA¦ÂÀþ°Ý¤ò²ð¤¹¤ë¤Î¤ËÂФ·¡¢PGE2¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤Ï¥«¥×¥µ¥¤¥·¥ó´¶¼õÀ­¤ÎCÀþ°Ý¤ò²ð¤¹¤ë¤³¤È¤«¤é¡¢¥¢¥í¥Ç¥£¥Ë¥¢¤Î£²¤Ä¤Î°Û¤Ê¤ëÈ¿±þ·ÐÏ©¡¢È¯¾Éµ¡¹½¤¬¤¢¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£ PGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤Ï¥â¥ë¥Ò¥Í¤ÎÄÃÄ˸ú²Ì¤¬¤ß¤é¤ì¤Ê¤¤¤³¤È¤«¤é¡¢¤³¤Îȯ¾Éµ¡¹½¤òÌÀ¤é¤«¤Ë¤¹¤ë¤³¤È¤ÏÈó¾ï¤Ë½ÅÍפǤ¢¤ë¡£PGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤òÆÃ°ÛŪ¤Ë¾Ã¼º¤µ¤»¤ë½èÃÖÊýË¡¤ò¸«¤¤¤À¤·¡¢½èÃÖ·²¤È̤½èÃÖ·²¤ÎÀÔ¿ñ¤«¤éÄ´À½¤·¤¿cDNA´Ö¤Î¥µ¥Ö¥È¥é¥¯¥·¥ç¥ó¤Ë¤è¤ê15¼ïÎà¤Î´ûÃΤΰäÅÁ»Ò¤È14¼ïÎà¤Î̤ÃΤΰäÅÁ»Ò¤òƱÄꤷ¤¿¡£¸Ä¡¹¤Î°äÅÁ»Ò¤Î±ö´ðÇÛÎóÁ´Ä¹¤ÎñΥ¤ÈÀÔ¿ñ¤Ç¤Î¡¡mRNA¤Îȯ¸½¤Î³Îǧ¤ò¹Ô¤Ã¤¿¡£¤³¤ì¤é°äÅÁ»Ò¤Î¥¢¥ó¥Á¥»¥ó¥¹¥ª¥ê¥´¤ò¹çÀ®¤·¤ÆÎ±ÃÖ¥«¥Æ¡¼¥Æ¥ë¤Ç1½µ´Ö¤ËÅϤêÀÔ¿ñ¤ËÅêÍ¿¤·¤¿¡£¤¤¤¯¤Ä¤«¤Î¥¢¥ó¥Á¥»¥ó¥¹¥ª¥ê¥´¤ÏPGF2¦Á¤Ë¤è¤ë¥¢¥í¥Ç¥£¥Ë¥¢¤òÍÞÀ©¤·¤¿¡£¤³¤ì¤é¤Î°äÅÁ»Ò¤Îµ¡Ç½²òÀϤò¤µ¤é¤Ë¿Ê¤á¤Æ¤¤¤ë¡£

ii)¡¡¿À·Ð¥Ú¥×¥Á¥ÉNoc/OFQ¤ÈNST¤Ë¤è¤ëÄ˳ÐÀ©¸æ¤Îʬ»Ò¥á¥«¥Ë¥º¥à
Noc/OFQ¤ÎÁ°¶îÂÎÃÁÇò¾å¤Ë¡¢Noc/OFQ¤Ë¤è¤ëÄ˳ÐÈ¿±þ¤òÍÞÀ©¤¹¤ëÀ¸Íý³èÀ­¥Ú¥×¥Á¥É¤òȯ¸«¤·¡¢¥Î¥·¥¹¥¿¥Á¥ó (NST)¤È̾¤Å¤±¤¿¡£NST¤ÈNoc/OFQ¤Ï¡¢ÀÔ¿ñ¸å³Ñ¤Ë¤ª¤¤¤Æ¤Ï¤È¤â¤ËɽÁؤ˸ºß¤·¡¢³Æ¡¹¤Î¼õÍÆÂΤò²ð¤·¤Æ¤½¤ÎºîÍѤòȯ´ø¤¹¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤Æ¤­¤¿¡£NST¤ÈNoc/OFQ¤Ë¤è¤ëÄ˳ÐÀ©¸æµ¡¹½¤òÌÀ¤é¤«¤Ë¤¹¤ë¤¿¤á¡¢NST¼õÍÆÂΤÎñΥƱÄê¤È¥Ú¥×¥Á¥É¤Î»ºÀ¸Í·Î¥µ¡¹½¤Î²òÌÀ¤ò¼´¤Ë¸¦µæ¤ò¿Ê¤á¤¿¡£


a)¡¡NST¼õÍÆÂÎ¤ÎÆ±Äê
¡¡125Iɸ¼±NSTͶƳÂΤò¹çÀ®¤·¡¢¥Þ¥¦¥¹ÀÔ¿ñËì²èʬ¤Ç¥Õ¥©¥È¥¢¥Õ¥£¥Ë¥Æ¥£¥é¥Ù¥ê¥ó¥°¤ò¹Ô¤Ã¤¿·ë²Ì¡¢Ìó33 kDa¤Î·ë¹çÃÁÇò¤¬ÆÃ°ÛŪ¤Ëɸ¼±¤µ¤ì¤¿¡£¤³¤ÎÃÁÇò¤Ï¡¢ºÙ˦Ëì¤Î¥é¥Õ¥È²èʬ¤Ë¸ºß¤·¡¢GTP¦ÃS¤Î½èÍý¤Ë¤è¤ê¾Ã¼º¤·¤¿¤³¤È¤«¤é¡¢GTP·ë¹çËìÃÁÇò¤Î²ÄǽÀ­¤¬¼¨º¶¤µ¤ì¤¿¡£¸½ºß¡¢¤³¤ÎÃÁÇò¤ÎÀºÀ½¡¢Æ±ÄêµÚ¤Ó°äÅÁ»Ò¤Î¥¯¥í¡¼¥Ë¥ó¥°¤ò»î¤ß¤Æ¤¤¤ë¡£
b)¡¡¥Ú¥×¥Á¥É¤Î»ºÀ¸Í·Î¥µ¡¹½
¡¡¥Ú¥×¥Á¥É¤Î»ºÀ¸¡¢Í·Î¥µ¡¹½¤ª¤è¤Ó¡¢»ºÀ¸Ä´Àá¤òô¤¦¤È¹Í¤¨¤é¤ì¤ë¥Ú¥×¥Á¥É¤Î¥×¥í¥»¥Ã¥·¥ó¥°¤Ë´ØÍ¿¤¹¤ëÃÁÇòʬ²ò¹ÚÁǤβòÌÀ¤òÌÜŪ¤È¤·¡¢À¸ÊªÈ¯¸÷ÃÁÇò¤ÎƳÆþ¤µ¤é¤Ë¡¢¤½¤ÎÃÁÇò´Ö¤Î¥¨¥Í¥ë¥®¡¼°Üư¤ò±þÍѤ·¤¿ÊýË¡(BRET)¤Î³ÎΩ¤ò»î¤ß¤¿¡£(ȯ¸÷¹ÚÁÇ)−(NST¡¦Noc/OFQ)−(GFP)¤ÎÍ»¹çÃÁÇò¤Î°äÅÁ»Ò¥Ù¥¯¥¿¡¼¤ò¹½ÃÛ¤·¡¢ºÙ˦¤ËƳÆþ¤·¤¿¡£¤³¤ÎÍ»¹çÃÁÇò¤Ï¡¢NST¡¦Noc/OFQ¥Ú¥×¥Á¥É¤¬¥×¥í¥»¥Ã¥·¥ó¥°¤µ¤ì¤Ê¤¤¾ì¹ç¤Ïȯ¸÷¹ÚÁǤθ÷¤Ï¥¨¥Í¥ë¥®¡¼°Üư¤Ë¤è¤ê¡¢GFP¤òÎ嵯¤·Î理Îȯ¸÷¤È¤Ê¤ë¤³¤È¤ò¡¢NST¡¦Noc/OFQ¥Ú¥×¥Á¥É¤¬¥×¥í¥»¥Ã¥·¥ó¥°¤µ¤ì¤¿¾ì¹ç¤Ï¡¢È¯¸÷¹ÚÁǼ«ÂΤÎÀÄ¿§¸÷¤òȯ¤¹¤ë¤³¤È¤òǧ¤á¤¿¤³¤È¤è¤ê¡¢¥Ú¥×¥Á¥É¤Î¥×¥í¥»¥Ã¥·¥ó¥°¤ò¥â¥Ë¥¿¡¼¤Ç¤­¤ë¥×¥í¡¼¥Ö¤¬³ÎΩ¤Ç¤­¤¿¡£¤µ¤é¤Ë¡¢È¯¿§¸÷¤ò»ØÉ¸¤Ë¥Ú¥×¥Á¥É¤Îʬ²ò²áÄø¤òÄÉÀפ·¡¢¥×¥í¥»¥Ã¥·¥ó¥°¹ÚÁǤΥ¯¥í¡¼¥Ë¥ó¥°¡¢Èù¼åȯ¸÷²òÀϸ²Èù¶ÀÁõÃ֤ˤè¤êȯ¸÷¤òÄÉÀס¢¥×¥í¥»¥Ã¥·¥ó¥°²áÄø¤Î¥ê¥¢¥ë¥¿¥¤¥à²òÀϤò»î¤ß¤Æ¤¤¤ë¡£

iii)¡¡¿¯³²À­»É·ã¤Ë¤è¤ë°äÅÁ»Òȯ¸½Í¶Æ³¤ÈÄ˳вáÉÒÈ¿±þ
¡¡PGI2¡Ê¥×¥í¥¹¥¿¥µ¥¤¥¯¥ê¥ó¡Ë¼õÍÆÂΡÊIP¡ËKO¥Þ¥¦¥¹¤Ç¤Ï¥«¥é¥²¥Ë¥ó¤Ë¤è¤ë±ê¾ÉÈ¿±þ¤ä¿Ý»À¥é¥¤¥¸¥ó¥°»î¸³¤ÇÄË³Ð¹ÔÆ°¤¬ÍÞÀ©¤µ¤ì¤ë¤Î¤ËÂФ·¡¢¥Û¥Ã¥È¥×¥ì¡¼¥È»î¸³¤ätail-flick»î¸³¤ÇÇ®»É·ã¤ËÂФ¹¤ëÈ¿±þ¤ËÊѲ½¤¬¤Ê¤«¤Ã¤¿¤³¤È¤«¤é¡¢PGI2¤ÏËö¾¿¤ÇÄ˳ÐÈ¿±þ¤Ë´ØÍ¿¤¹¤ë¤³¤È¤¬¼¨º¶¤µ¤ì¤Æ¤¤¤¿¡£Â­í¨¤Ë¥«¥é¥²¥Ë¥ó¤òÃí¼Í¤·¤Æ£±»þ´Ö¤«¤éCOX-2¤Î£íRNA¤È¤È¤â¤Ë¡¢IP¼õÍÆÂΣíRNA¤Îȯ¸½¤¬Áý²Ã¤·¤¿¡££¶»þ´Ö¸å¤ËIP¼õÍÆÂÎºîÆ°Ìô¤ò¿ñ¹ÐÆâ¤ËÃíÆþ¤¹¤ë¤È½èÃÖ¦¡¢Ì¤½èÃÖ¦¤È¤â¤ËÄ˳вáÉÒÈ¿±þ¤¬À¸¤¸¤¿¡£Ëö¾¿Éô°Ì¤Î±ê¾É¤Ëȼ¤Ã¤Æ¡¢¤³¤ì¤Þ¤Çȯ¸½¤·¤Æ¤¤¤Ê¤«¤Ã¤¿IP¼õÍÆÂΤ¬Í¶Æ³¤µ¤ì¡¢»ºÀ¸¤¬Áý²Ã¤·¤¿PGI2¤¬IP¼õÍÆÂΤò³èÀ­²½¤·¤ÆÃæ¿õÀ­¤ËÄ˳ÐÅÁã¤Ë´ØÍ¿¤¹¤ë·ë²Ì¤Ï¡¢¿¯³²À­»É·ã¤Î»ý³¤Ë¤è¤êͶƳ¤µ¤ì¤ëÀ¸Âΰø»Ò¤Î´ØÍ¿¤ÏKO¥Þ¥¦¥¹¤Ç¤Ï¸«Íî¤È¤µ¤ì¤ë²ÄǽÀ­¤ò¼¨º¶¤¹¤ë¤â¤Î¤Ç¤¢¤ë¡£

iv)¡¡¥¢¥í¥Ç¥£¥Ë¥¢¤Ë´Ø¤¹¤ë¿À·Ð²óÏ©Ì֤ζõ´ÖŪ¤ª¤è¤Ó»þ´ÖŪ¥¤¥á¡¼¥¸¥ó¥°
¡¡ ÄË¤ß¤ÎÆ°Êª¥â¥Ç¥ë¤è¤êÆÀ¤¿¥¢¥í¥Ç¥£¥Ë¥¢¤Î¹ÔưÌôÍý³ØÅª·ë²Ì¤ò´ð¤Ë¡¢¥Ó¥Ç¥ª¥Þ¥¤¥¯¥í¥¹¥³¥Ô¡¼¤Ë¤è¤ë¥¤¥á¡¼¥¸¥ó¥°Ë¡¤òÍѤ¤¤Æ¥¢¥í¥Ç¥£¥Ë¥¢Í¶Æ³¤Ë´ØÍ¿¤¹¤ë¿À·Ð²óÏ©¤ÎÆó¼¡¸µÅª²Ä»ë²½¤ò»î¤ß¤Æ¤¤¤ë¡£¤½¤Î²óÏ©¤Ë¤ª¤±¤ëPG¤äÄ˳Ф˴ØÏ¢¤¹¤ë¿À·Ð¥Ú¥×¥Á¥ÉÎà¤ÎºîÍѵ¡¹½¤Î¥¤¥á¡¼¥¸¥ó¥°¤ò¸÷³ØÅªËìÅŰ̡¢ºÙ˦Æâ¥«¥ë¥·¥¦¥à¥¤¥ª¥óÇ»ÅÙ¡Ê[Ca2+]i¡Ë¡¢NO¤Ë¤Ä¤¤¤ÆÃ±ÆÈ¤¢¤ë¤¤¤ÏƱ»þ¤ËÆó½ÅÀ÷¿§¤·¤Æ¿ë¹Ô¤·¡¢¹ÔưÌôÍý³ØÅª·ë²Ì¤ÈÈæ³Ó¸¡Æ¤¤·¤Æ¤¤¤ë¡£Îã¤òµó¤²¤ë¤È¡¢PGF¼õÍÆÂÎ (FP) KO¥Þ¥¦¥¹¤ÎÀÔ¿ñ¥¹¥é¥¤¥¹É¸Ëܤˤª¤±¤ë[Ca2+] i ưÂÖ¤ò¥¤¥á¡¼¥¸¤·¤¿¤È¤³¤í¡¢ÀÔ¿ñ¸å³Ñ¤ÎIVÁØÉí¶á¤Ç¡¢¥ª¥Ô¥ª¥¤¥É¼õÍÆÂΤγƼ異¥´¥Ë¥¹¥ÈU50488H (¦Ê¼õÍÆÂÎ)¡¢DPDPE¡Ê¦Ä¼õÍÆÂΡˡ¢DAMGO¡Ê¦Ì¼õÍÆÂΡˤ¬[Ca2+] i ¾å¾º¤ò°ú¤­µ¯¤³¤·¡¢U50488H¤¬ºÇ¤âÂ礭¤Ê[Ca2+] i ¾å¾º¤ò°ú¤­µ¯¤³¤¹¤³¤È¤ò¸«¤¤¤À¤·¤¿¡£L5·ëå§¥â¥Ç¥ë¤ÇÄ˳вáÉÒÈ¿±þ¤ò°ú¤­µ¯¤³¤¹¸ÄÂΤòÍѤ¤¤ÆÀÔ¿ñ¤Ë¤ª¤±¤ëNO»ºÀ¸¤òNO¥×¥í¡¼¥Ö»îÌô¤ÎDAF-FM¤òÍѤ¤¤Æ¥¤¥á¡¼¥¸¥ó¥°¤·¤¿¤È¤³¤í¡¢·ë姤·¤¿Â¦¤ÎNO¾å¾º¤¬È¿ÂΦ¤è¤ê¤âÂ礭¤¤·¹¸þ¤Ë¤¢¤ë¤³¤È¤ò´Ñ»¡¤·¤¿¡£¥°¥ë¥¿¥ß¥ó»ÀͶƳÂΤǤÏ[Ca2+] i ưÂÖ¤ÈNOưÂ֤˲òÎ¥¤¬¸«¤¤¤À¤µ¤ì¤¿¡£¤³¤Î¤è¤¦¤Ë¡¢ÀÔ¿ñ¥¹¥é¥¤¥¹¤òÍѤ¤¤ë¥¤¥á¡¼¥¸¥ó¥°¼Â¸³¤Ï¡¢Ä˳ФοÀ·Ð²óÏ©ÌÖ¤ò²òÀϤ¹¤ë¼êÃʤȤ·¤Æ´üÂÔ¤µ¤ì¤ë¡£

£²¡Ë´Îµ¡Ç½Ä´Àá°ø»Ò¤È¤·¤Æ¤Î¥µ¥¤¥È¥«¥¤¥ó¤ÎÌò³ä
¡¡ÉÂÂÖ»þ¤Î´Î¡¤Ç¤Ï¡¢±ê¾ÉÀ­¥µ¥¤¥È¥«¥¤¥ó¤Ë¤è¤ëÍÍ¡¹¤Ê°äÅÁ»Ò¤Îȯ¸½Í¶Æ³¤¬¤½¤Îµ¡Ç½ÉÔÁ´¤È¿¼¤¯´ØÏ¢¤·¤Æ¤¤¤ë¡£¥¤¥ó¥¿¡¼¥í¥¤¥­¥ó1¦Â (IL-1¦Â) ¤Ê¤É¤Ë¤è¤êͶƳ¤µ¤ì¤ëͶƳ·¿°ì»À²½ÃâÁǹçÀ®¹ÚÁÇ¡ÊiNOS¡Ë¤Ï¿Î̤ÎNO¤ò»ºÀ¸¤¹¤ë¡£NO¤Ï´Î¾ã³²¤½¤Î¤â¤Î¤ò°ú¤­µ¯¤³¤·¤µ¤é¤Ë°­²½¤µ¤»¤ëºîÍѤȵդˤ½¤Î¾ã³²¤ò¸º¼å²½¤¹¤ëÁêÈ¿¤¹¤ë£²¤Ä¤ÎºîÍѤò¤â¤Ä¡£¤·¤«¤·¤Ê¤¬¤éž¼Ì°ø»ÒNF-¦ÊB¤ò²ð¤·¤¿iNOSͶƳ¤ÎÀ©¸æ¥á¥«¥Ë¥º¥à¤Î¾ÜºÙ¤ÏÉÔÌÀ¤ÊÅÀ¤¬Â¿¤¤¡£º£Ç¯ÅÙ¤ÏÆ°Êª¥â¥Ç¥ë¡¢½éÂåÇÝÍܴκÙ˦¤È¾®Ä²³ôºÙ˦¤òÍѤ¤¤Æ¡¢iNOS/NOͶƳ¤ÎºîÍѵ¡¹½¤òÌÀ¤é¤«¤Ë¤·¤¿¡£

i)¡¡´ÎÅüÂå¼Õ¤ÈNO»ºÀ¸Í¶Æ³¤È¤Î´Ø·¸
´Î´â¤Ê¤É¤Î¼ê½Ñ¤Ë¤ª¤¤¤Æ¡¢´ÎÉôʬÀÚ½ü¸å¤Î´¶À÷¡¢±ê¾É¤Ë¤è¤ê´Îµ¡Ç½ÉÔÁ´¤¬µ¯¤³¤ë¡£NO¤Ï´Îµ¡Ç½Äã²¼¤Ë´ØÍ¿¤·¤Æ¤¤¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤ë¤¬ÉÔÌÀ¤ÊÅÀ¤¬Â¿¤¤¡£NO ¤Ë¤ÏiNOS°Ê³°¤Ë¹½À®·¿NOS (cNOS)¤¬¤¢¤ê¡¢ÁªÂòŪNOSÁ˳²Ìô¤¬¤Ê¤¤¸½¾õ¤Ç¤Ï¡¢´Îµ¡Ç½¤Ë¤É¤ÎNOS¤¬´ØÍ¿¤¹¤ë¤Î¤«·ëÏÀ¤Å¤±¤ë¤³¤È¤ÏÆñ¤·¤¤¡£º£Ç¯ÅÙ¡¢ÌîÀ­·¿¥Þ¥¦¥¹¤ÈiNOS-KO ¥Þ¥¦¥¹¤«¤é½éÂåÇÝÍܴκÙ˦¤òÄ´À½¤·¡¢LPS¤ÈIL-1¦Â¡¢TNF¦Á¡¢INF¦Ã¤Î¥µ¥¤¥È¥«¥¤¥óº®¹ç±Õ (CM) ¤ÇͶƳ¤µ¤ì¤ëiNOSͶƳ¤È¥¨¥Í¥ë¥®¡¼Âå¼Õ¤È¤Î´Ø·¸¤ò¸¡Æ¤¤·¤¿¡£iNOS¤Ë¤è¤ê»ºÀ¸¤µ¤ì¤ë NO¤Ï´ÎºÙ˦¤ÎATP¥ì¥Ù¥ë¤ä¥±¥È¥óÂÐÈæ¤Ê¤É¥¨¥Í¥ë¥®¡¼Âå¼Õ¤Ë´ØÍ¿¤¹¤ë¤¬¡¢¥¤¥ó¥¹¥ê¥ó¤Ë¤è¤ë¥°¥ê¥³¡¼¥²¥ó¹çÀ®¤Ë¤Ï´ØÍ¿¤·¤Ê¤¤¤È¤¤¤¦ÌÀ²ò¤Ê·ëÏÀ¤¬ÆÀ¤é¤ì¤¿¡£¤³¤Î·ë²Ì¤Ï¡¢´ÎÉôʬÀÚ½ü¥é¥Ã¥È¥â¥Ç¥ë¤Î·ë²Ì¤È¤â°ìÃפ·¡¢ATP¥ì¥Ù¥ë¤Î¸º¾¯¤ÏNOÁý²Ã¤Ë¤è¤ë¥ß¥È¥³¥ó¥É¥ê¥¢µ¡Ç½ÉÔÁ´¤ËͳÍ褹¤ë¤È¹Í¤¨¤é¤ì¤ë¡£¤³¤ì¤é¤Î·ë²Ì¤Ï¡¢iNOS¤Ë¤è¤ëNO»ºÀ¸¤ÎÂ¥¿Ê¤òÍÞÀ©¤¹¤ë¤³¤È¤¬´Îµ¡Ç½Äã²¼¤ÎËɻߤËÂ礭¤¯¹×¸¥¤¹¤ë¤³¤È¤ò¼¨º¶¤·¤Æ¤¤¤ë¡£

ii)¡¡¾®Ä²³ôºÙ˦¤Ë¤ª¤±¤ëiNOS¤ÎͶƳ
¡¡¤³¤ì¤Þ¤Ç¡¢EGF¤¬¾®Ä²°Ü¿¢¤Îµ¡Ç½²óÉü¤òÂ¥¿Ê¤¹¤ë¤³¤È¤òÊó¹ð¤·¤Æ¤­¤¿¤¬¡¢EGF¤ÎºîÍѵ¡½ø¤òÌÀ¤é¤«¤Ë¤¹¤ë¤¿¤á¤Ë¡¢¾®Ä²³ôºÙ˦¤Ç¤ÎiNOSͶƳ¤ËµÚ¤Ü¤¹¸ú²Ì¤ò¸¡Æ¤¤·¤¿¡£½éÂåÇÝÍܴκÙ˦¤È°Û¤Ê¤ê¡¢¾®Ä²³ôºÙ˦¤Ç¤Ï¡¢IL-1¦Â¤ÇiNOS¤ÎͶƳ¤Ïµ¯¤³¤é¤º¡¢EGF¤òź²Ã¤¹¤ë¤³¤È¤Ç¤Ï¤¸¤á¤ÆiNOS¤¬Í¶Æ³¤µ¤ì¡¢·ÑÂå¤ò³¤±¤ë¤³¤È¤Ë¤è¤ê¡¢EGF¤Î´óÍ¿¤¬Äã²¼¤¹¤ë¤È¤¤¤¦¶½Ì£¿¼¤¤¼Â¸³·ë²Ì¤¬ÆÀ¤é¤ì¤¿¡£¡¡

£³¡Ë¡¡À¸¿£´ï·Ï¤Ë¤ª¤±¤ë movo°äÅÁ»Ò¤ÎKO¥Þ¥¦¥¹¤ÎºîÀ½
¡¡Ó®Æýưʪ¤Ë¤ª¤±¤ëÀ¸¿£ºÙ˦¤Îʬ²½µ¡¹½¤Îʬ»Ò¥ì¥Ù¥ë¤Ç¤Î²òÀϤòÌÜŪ¤È¤·¤Æ¡¢¥·¥ç¥¦¥¸¥ç¥¦¥Ð¥¨¤ÇÍñÁã¤Îʬ²½¤ª¤è¤ÓÍñ·ÁÀ®¤Ë´Ø¤ï¤ëovo°äÅÁ»Ò¤Î¥Þ¥¦¥¹¥Û¥â¥í¥°¤Î¥¯¥í¡¼¥Ë¥ó¥°¤ò»î¤ß¡¢¥Þ¥¦¥¹ÁêÆ±°äÅÁ»Ò¤Ç¤¢¤ëmovo°äÅÁ»Ò¤ÎñΥ¤ËÀ®¸ù¤·¤¿¡£¹½Â¤²òÀϤηë²Ì¡¢movo¤Îž¼Ì»ºÊª¤¬Zn¥Õ¥£¥ó¥¬¡¼DNA·ë¹ç¥â¥Á¡¼¥Õ¤òÍ­¤¹¤ë³Ë¥¿¥ó¥Ñ¥¯¤Ç¤¢¤ë¤³¤È¡¢µÚ¤Ó¤½¤ÎmRNA¤Ï¥Þ¥¦¥¹¤Ç¤ÏÀ¸¸å£³½µÎð°Ê¹ß¤ÎÀºÁã¤ÇÆÃ°ÛŪ¤Ëȯ¸½¤·¤Æ¤¤¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£¤½¤Î¸å¤Î²òÀϤˤè¤Ã¤Æ¡¢mOVOÃÁÇò¤¬¼ÂºÝ¤ËDNA¤ÎÆÃÄê¤Î±ö´ðÇÛÎó¤Ë·ë¹ç¤·¤Æ¤ª¤ê¡¢Å¾¼ÌÀ©¸æÎΰè¤Ë¤½¤ÎÇÛÎó¤ò´Þ¤à°äÅÁ»Ò¤Îž¼Ì³èÀ­¤òin vitro¤ÎÇÝÍܷϤÇÊÑÆ°¤µ¤»¤ë¤³¤È¡¢ÍñÁã·ÁÀ®ÉÔǽ¤Îovo-/-¥·¥ç¥¦¥¸¥ç¥¦¥Ð¥¨¤Ëmovo¤òÌ᤹¤ÈÉôʬŪ¤ËÍñ·ÁÀ®¤¬¤ß¤é¤ì¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£movo°äÅÁ»Ò¤ÎKO¥Þ¥¦¥¹¤Ïlethal¤ÇÂÛÈ×·ÁÀ®¤Ë°Û¾ï¤¬Ç§¤á¤é¤ì¤¿¡£Å¾¼Ì°ø»Ò¤È¤·¤Æmovo¤¬¤É¤Î¤è¤¦¤Ë´ØÍ¿¤¹¤ë¤Î¤«¡¢¤µ¤é¤Ëconditional KO¥Þ¥¦¥¹¤ÎºîÀ½¤ò¹Ô¤¤¡¢mOVOÃÁÇò¤¬¤É¤Î¤è¤¦¤ËÀº»Ò·ÁÀ®¤Ë´ØÍ¿¤¹¤ë¤Î¤«²òÌÀ¤ò¿Ê¤á¤Æ¤¤¤ë¡£

¡Ô¸¦µæ¶ÈÀÓ¡Õ

³Ø²ñ»ïÅù

  1. Yasuda K, Okumura T, Okada H, Nakajima T, Aoki J, Arai H, Inoue K, Nishizawa M, Ito S and Kanzaki H(2001)
    Platelet-activating factor acetylhydrolase isoforms­µand ­¶in human uterus. comparisons with pregnant uterus and myoma.
    Biol Reprod 64:339-344
  2. Kaibori M, Inoue T, Tu W, Oda M, Kwon A-H, Kamiyama Y and Okumura T(2001)
    FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes
    Life Sci 69:17-26
  3. Minami T, Matsumura S, Okuda-Ashitaka E, Shimamoto K, Sakimura K, Mishina M, Mori, H and Ito S(2001)
    Characterization of the glutamatergic system for induction and maintenance of allodynia.
    Brain Res 895:178-185
  4. Minami T, Bakoshi S, Nakano H, Mine O, Muratani T, Mori H and Ito S(2001)
    The effects of capsaicin cream on prostaglandin-induced allodynia.
    Anesth Analg 93:419-423
  5. Minami T, Nakano H, Kobayashi T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S and Ito S(2001)
    Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice.
    Br J Pharmacol 133:438-444
  6. Inoue M, Takahashi S, Yamashina I, Kaibori M, Okumura T, Kamiyama Y, Vichier-Guerre S, Cantacuzene D and Nakada H(2001)
    High density O-glycosylation of the MUC2 tandem repeat unit by N-acetylgalactosaminyltransferase-3 in colonic adenocarcinoma extracts.
    Cancer Res 61:950-956
  7. Oyaizu H, Adachi Y, Okumura T, Okigaki M, Oyaizu N, Taketani S, Ikebukuro K, Fukuhara S and Ikehara S(2001)
    Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line.
    Oncol Rep 8:825-829
  8. Maruyama R, Kawata A, Ono S, Nishizawa M, Ito S and Inoue M(2001)
    Effects of amino acids on the amidation of polyaromatic carboxylic acids by Bacillus cereus.
    Biosci Biotech Biochem 65:1761-1765
  9. Maruyama R, Nishizawa M, Itoi Y, Ito S and Inoue M(2001)
    Isolation and expression of a Bacillus cereus gene encoding benzil reductase.
    Biotech Bioeng 75:630-633
  10. Doi Y, Minami T, Nishizawa M, Mabuchi T, Mori H and Ito S(2001)
    Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation.
    Neuroreport 13:93-96
  11. Kato Y, Hamada Y, Nakai K, Kitagawa K, Ito S, Okumura T and Hioki K(2002)
    Effect of epidermal growth factor on intestinal adaptation after allogeneic small bowel transplantation in rats.
    Life Sci 70: 809-819
  12. Kaibori M, Inoue T, Oda M, Naka D, Kawaguchi T, Kitamura N, Miyazawa K, Kwon A-H, Kamiyama Y and Okumura T (2002)
    Exogenously administered HGF-activator augments liver regeneration through the production of biologically active HGF.
    Biochem Biophys Res Commun 290: 475-481
  13. Maruyama R, Nishizawa M, Itoi Y, Ito S and Inoue M(2002)
    The enzymes with benzil reductase activity conserved from bacteria to mammals.
    J Biotechnol 94: 157-169
  14. Okuda-Ashitaka E, Minami T and Ito S(2002)
    Pain transmission regulated by novel neuropeptides nocistatin and nociceptin/orphanin FQ.
    J Biol Macromol 2: 3-10
  15. Tanikawa N, Ohmiya Y, Ohkubo H, Hashimoto K, Kangawa K, Kojima M, Ito S and Watanabe K(2002)
    Identification and characterization of a novel type of membrane-associated prostaglandin E synthase.
    Biochem Biophys Res Commun 291:884-889
  16. Kitano M, Okumura T, Nishizawa M, Liew FY, Seki T, Inoue K and Ito S(2002)
    Altered response to inflammatory cytokines in energy metabolism in inducible nitric oxide synthase knockout mice.
    J Hepatol 36:759-765



Áí¡¡¡¡Àâ

  1. Æî¡¡ÉÒÌÀ¡¢°ËÆ£À¿Æó¡Ê2001¡Ë
    ÄˤߤβÄÁºÀ­.
    À¸ÊªÊªÍý 41:15-19
  2. ³¤ËÙ¾»¼ù¡¢°æ¾åÃεס¢ÅÚ²°±Ñ¿Í¡¢²£°æÀµð¡¢ÜÞ¡¡²í·û¡¢¾å»³¡¡ÂÙÃË¡¢±ü¼Ãé˧¡Ê2001¡Ë
    ´Î¡¤ÎÄã»ÀÁǾ㳲¤ËÂФ¹¤ëFK506¤ÎÊݸî¸ú²Ì.
    º£Æü¤Î°Ü¿¢ 14:61-66
  3. Ito S, Okuda-Ashitaka E and Minami T (2001)
    Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin.
    Neurosci Res 41: 299-332
  4. °ËÆ£À¿Æó¡¢¾¾Â¼¿­¼£¡¢Æî¡¡ÉÒÌÀ¡Ê2002¡Ë
    À¸²½³Ø¤ÎΩ¾ì¤«¤é¤ß¤¿ÄˤߤÎʬ»Òµ¡¹½¤È¼£ÎÅ
    ¥Ú¥¤¥ó¥¯¥ê¥Ë¥Ã¥¯ 23: 363-368
³Ø²ñȯɽ
  1. Ito S (2001)
    Roles of prostaglandins in nociception.
    7th International Congress on PAF and Lipid Mediators, Tokyo
  2. Mine O, Matsumura S, Minami T, Sakai M, Okuda K, Takahashi H, Oka S, Kojima H, Nagano T, Fukasaku N, Mori H and Ito S (2001)
    Production of nitric oxide by prostaglandin E2 in NG 108-15 cells.
    The 31st Annual Meeting of Society for Neuroscience, San Diego, U.S.A.
  3. Ito S, Yamada H, Nakano H, Kobayashi T, Sugimoto Y, ushikubi F, Ichikawa A, Narumiya S, Mori H and Minami T (2001)
    Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by EP1 and EP3 knockout mice.
    The 31st Annual Meeting of Society for Neuroscience, San Diego, U.S.A.
  4. Muratani T, Minami T, Nakano H, Okuda-Ashitaka E, Maekawa M, Mori H and Ito S (2001)
    Effect of JTC-801, a novel nociceptin (Noc/OFQ) receptor antagonist, on pain responses in the formalin test.
    The 31st Annual Meeting of Society for Neuroscience, San Diego, U.S.A.
  5. Minami T, Matsumura S, Okuda-Ashitaka E, Shimamoto K, Imamura K, Mishina M, Mori H and Ito S (2001)
    Characterization of the glutamatergic system for induction and maintenance of PG-induced allodynia.
    The 31st Annual Meeting of Society for Neuroscience, San Diego, U.S.A.
  6. Nakai K, Hamada Y, Kitagawa K, Kato Y and Okumura T (2001)
    Effect of epidermal growth factor on the induction of dipeptide co-transporter after allogeneic small bowel transplantation.
    VII International Small Bowel Transplantation Symposium, Stockholm, Sweden.
  7. Kitagawa K, Hamada Y, Nakai K, Kato Y and Okumura T (2001)
    Comparison of one- and two-step procedures in a rat model of small bowel transplantation.
    VII International Small Bowel Transplantation Symposium, Stockholm, Sweden.
  8. Tachibana S, Lee T-L, Ricos MG, Fung FMY, Zhang G, Chen F-G, Chou N, Okuda-Ashitaka E, Ito S, Nishiuchi Y and Kimura T (2001)
    Comparison of nocistatin levels in CSF among chronic acute, non-pain patients and normal volunteers.
    The 32nd International Narcotics Research Conference.
  9. °ËÆ£À¿Æó¡¢°²¹â·ÃÈþ»Ò (2001)
    ¥Î¥·¥¹¥¿¥Á¥ó¤È¥Î¥·¥»¥×¥Á¥ó¤Ë¤è¤ëÄ˳ÐÄ´Àᵡ¹½
    Â裵²ó¿À·ÐÅÁãʪ¼Á¸¦µæ²ñ¡¢Åìµþ
  10. Watanabe K, Yamamoto-Suzuki T, Nishizawa M, Tsutsui Y, Ishimura K and Ito S (2001)
    Prostaglandin F synthase.
    Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
  11. ³¤ËÙ¾»¼ù¡¢°æ¾åÃεס¢¾®ÅÄÆ»Éס¢Ë­ÅçÌС¢ÃæÀ¾±Ñ¼ù¡¢´î¿¼ľ¼Â¡¢µÜß··ÃÆó¡¢ÜÞ²í·û¡¢¾å»³ÂÙÃË¡¢±ü¼Ãé˧ (2001)
    ³°°øÀ­HGF activator¤Ë¤è¤ë70%´ÎÉôʬÀÚ½ü¥é¥Ã¥È¤Î´ÎÆâHGF¤Î³èÀ­²½
    Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
  12. Tu Wei¡¢Ë̽йÀ¾Ï¡¢Î¤°æÁÔÊ¿¡¢ÃæÀ¾±Ñ¼ù¡¢Ë­ÅçÌС¢³¤ËÙ¾»¼ù¡¢ÜÞ²í·û¡¢¾å»³ÂÙÃË¡¢±ü¼Ãé˧ (2001)
    Êĺ¿À­²«áդˤè¤ë°ì»À²½ÃâÁǤλºÀ¸Â¥¿Ê¤Ï´Îµ¡Ç½¾ã³²¤Ë´ØÍ¿¤¹¤ë
    Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
  13. °ËÆ£À¿Æó¡¢¾¾Â¼¿­¼£¡¢°²¹â·ÃÈþ»Ò¡¢ÅçËÜ·¼»Ò¡¢»°Éʾ»Èþ¡¢ÆîÉÒÌÀ (2001)
    ÀÔ¿ñ¤ÎÄ˳ÐÅÁã¤Ë¤ª¤±¤ë¥°¥ë¥¿¥ß¥ó»À¤ÎÌò³ä
    Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
  14. À¾ß·´´Íº¡¢´Ý»³Îå¼£¡¢»å°æÂÙ¡¢°æ¾åÀµÈþ¡¢°ËÆ£À¿Æó (2001)
    ºÙ¶Ý¤«¤éÓ®ÆýÎà¤Þ¤ÇÊݸ¤µ¤ì¤Æ¤¤¤ë¥Ù¥ó¥¸¥ë´Ô¸µ¹ÚÁǤβòÀÏ
    Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
  15. ÇÏÞ¼·½À¸¡¢¹¾¸ýľÈþ¡¢Î¢½ÐÎÉÇî¡¢ÉðÆ£À¿¡¢°ËÆ£À¿Æó (2001)
    ¿À·Ð°øÀ­áÖÄˤˤª¤±¤ë¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥ó¤Î´ØÍ¿
    Âè74²óÆüËÜÀ¸²½³Ø²ñ¡¢µþÅÔ
  16. °ËÆ£À¿Æó (2001)
    ¥Î¥Ã¥¯¥¢¥¦¥È¥Þ¥¦¥¹¤òÍѤ¤¤¿Ä˳ÐÈ¿±þ¤Î²òÀÏ
    ¡ÖÁÏÌôÌôÍý¥Õ¥©¡¼¥é¥à¡×Â裲£µ²óÃÌÏòñ, Åìµþ
  17. °ËÆ£À¿Æó (2001)
    ¿À·Ð°øÀ­áÖÄˤÎʬ»Òµ¡¹½
    Â裳£µ²óÆüËÜ¥Ú¥¤¥ó¥¯¥ê¥Ë¥Ã¥¯³Ø²ñÂç²ñ¡¢´ôÉì
  18. °ËÆ£À¿Æó (2001)
    »é¼Á¥á¥Ç¥£¥¨¡¼¥¿¡¼¤ÈÄˤ߼õÍÆ
    Â裲£´²óÆüËÜ¿À·Ð²Ê³Ø¡¦Â裴£´²óÆüËÜ¿À·Ð²½³Ø¡¡¹çƱÂç²ñ¡¢µþÅÔ
  19. °ËÆ£À¿Æó (2001)
    ¥Î¥Ã¥¯¥¢¥¦¥È¥Þ¥¦¥¹¤òÍѤ¤¤¿ÄË¤ß¤Î¹ÔÆ°²òÀÏ
    °äÅÁ»ÒƳÆþ¸¦µæ²ñ¡¢Åìµþ
  20. °ËÆ£À¿Æó (2001)
    À¸Êª¿·µ¡Ç½¤ÈÁÏÌô¤ò¤á¤¶¤¹À¸ÂÎÆâʬ»Ò²Ê³Ø
    ³Ø½ÑÁÏÀ®Â裱²ó¥·¥ó¥Ý¥¸¥¦¥à
  21. Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢²ÃÆ£ÂÙµ¬¡¢ËÌÀî¹îɧ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
    ¥é¥Ã¥È°Û·Ï¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëepidermal growth factor (EGF) ¤ÎÅü¤ª¤è¤Ó¥¸¥Ú¥×¥Á¥ÉÍ¢Á÷óÂΤ˴ؤ¹¤ë¸¡Æ¤
    Âè16²óÀÅÌ®·ÐIJ³Ø²ñ¡¢²£ÉÍ
  22. Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢²ÃÆ£ÂÙµ¬¡¢ËÌÀî¹îɧ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
    ¥é¥Ã¥È¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëEGF¤¬µÚ¤Ü¤¹°Ü¿¢Ä²´ÉÇ´Ëì¤ÎÅü¾Ã²½µÛ ¼ýÂ¥¿Ê¸ú²Ì¤Î¸¡Æ¤
    Âè101²óÆüËܳ°²Ê³Ø²ñ¡¢ÀçÂæ
  23. Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢²ÃÆ£ÂÙµ¬¡¢ËÌÀî¹îɧ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
    ¥é¥Ã¥È¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëEGF¤Î¸ú²Ì¡¦ÆóÅüÎàʬ²ò¹ÚÁǤÈNa+/¥°¥ë¥³¡¼¥¹Í¢Á÷ÂÎ
    Âè38²ó¾®»ù³°²Ê³Ø²ñ¡¢Åìµþ
  24. ³¤ËÙ¾»¼ù¡¢°æ¾åÃεס¢¾®ÅÄÆ»Éס¢ÜÞ²í·û¡¢±ü¼Ãé˧¡¢¾å»³ÂÙÃË (2001)
    ´Î¡¤ÎÄã»ÀÁÇ¡¦ºÆ»ÀÁDz½¤Î˦¾ã³²¤ËÂФ¹¤ëFK506¤ÎÊݸî¸ú²Ì
    Âè101²óÆüËܳ°²Ê³Ø²ñ¡¢ÀçÂæ
  25. ³¤ËÙ¾»¼ù¡¢Ë­ÅçÌС¢ÃæÀ¾±Ñ¼ù¡¢µÜß··ÃÆó¡¢´î¿¼ľ¼Â¡¢ÜÞ²í·û¡¢¾å»³ÂÙÃË¡¢±ü¼Ãé˧ (2001)
    ³°°øÀ­HGF³èÀ­²½°ø»Ò¤Ë¤è¤ë´ÎÉôʬÀÚ½ü¥é¥Ã¥È¤Î´ÎºÆÀ¸¤ÎÂ¥¿Ê
    Âè8²ó´ÎºÙ˦¸¦µæ²ñ¡¢Åìµþ
  26. °æ¾åÃεס¢ÃæÀ¾±Ñ¼ù¡¢Ë­ÅçÌС¢³¤ËÙ¾»¼ù¡¢À¾ß·´´Íº¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧(2001)
    Äã»ÀÁǤˤª¤±¤ë´ÎºÙ˦¤Î°ì»À²½ÃâÁǹçÀ®¹ÚÁÇȯ¸½Í¶Æ³¤ÎÍÞÀ©¤È¤½¤Îµ¡¹½
    Âè48²óÆüËÜÀ¸²½³Ø²ñ¶áµ¦»ÙÉôÎã²ñ¡¢ÆàÎÉ
  27. Ãæ°æ¹¨¼£¡¢ßÀÅĵȧ¡¢ËÌÀî¹îɧ¡¢²ÃÆ£ÂÙµ¬¡¢ÇÏÅÂŰÌ顢ʡÅĽ¨ÌÀ¡¢°ËÆ£À¿Æó¡¢±ü¼Ãé˧¡¢ÆüÃֹɻÎϺ (2001)
    ¥é¥Ã¥È¾®Ä²°Ü¿¢¤Ë¤ª¤±¤ëEGF¤Î¸ú²Ì¡¦PepT1ȯ¸½¤ÈÆóÅüÎàʬ²ò¹ÚÁÇȯ¸½¤Ë¤Ä¤¤¤Æ
    Â裴²ó¶áµ¦ÉÂÂÖ¸¦µæ²ñ¡¢Âçºå
  28. À¾ß·´´Íº¡¢´Ý»³Îå¼£¡¢»å°æÂÙ¡¢°æ¾åÀµÈþ¡¢°ËÆ£À¿Æó (2001)
    ¥»¥ì¥¦¥¹¶Ý¤Î¥Ù¥ó¥¸¥ë´Ô¸µ¹ÚÁÇ¡¢¹ÚÊì¤ÎYIR036CÃÁÇò¼Á¤È¥¹¥Ê¥Í¥º¥ß¤Î ¥»¥Ô¥¢¥×¥Æ¥ê¥ó´Ô¸µ¹ÚÁǤÎÈæ³Ó
    Â裲£´²óÆüËÜʬ»ÒÀ¸Êª³Ø²ñ¡¢²£ÉÍ
  29. °²¹â·ÃÈþ»Ò¡¢ÆîÉÒÌÀ¡¢°ËÆ£À¿Æó (2001)
    ÄˤߤÎʬ»Òµ¡¹½
    ÆüËÜÀ¸Êª¹âʬ»Ò³Ø²ñ2001ǯÅÙÂç²ñ¡¢µþÅÔ
Ãø¡¡¡¡½ñ

  1. °ËÆ£À¿Æó¡¢°²¹â·ÃÈþ»Ò¡¢Æî¡¡ÉÒÌÀ¡Ê2001¡Ë
    Äˤ߸¦µæ¤ÎºÇÁ°Àþ¡¡¥Î¥·¥»¥×¥Á¥ó´ØÏ¢¡¡¥Î¥·¥¹¥¿¥Á¥ó¤ÎÄÃÄ˺îÍÑ ¥ª¥Ô¥ª¥¤¥É¼£ÎÅ
    ²ÝÂê¤È¿·Ä¬Î®¡Ê¥ß¥¯¥¹¡Ë260-267ÊÇ.
  2. °ËÆ£À¿Æó¡¢°²¹â·ÃÈþ»Ò¡Ê2001¡Ë
    ¥Î¥·¥¹¥¿¥Á¥ó¤È¥Î¥·¥»¥×¥Á¥ó¤Ë¤è¤ëÄ˳ÐÄ´Àᵡ¹½ ¿À·Ð¥Ú¥×¥¿¥¤¥É¡¡ºÇ¿·¤ÎÏÃÂê¡¡
    Â裵²ó¿À·ÐÅÁãʪ¼Á¸¦µæ²ñµ­Ï¿½¸¡Êº´Æ£¸øÆ»¡¡ÊÔ½¸¡Ë2-9ÊÇ,¡¡¥¨¥¯¥»¥×¥¿¥á¥Ç¥£¥«
  3. Æî¡¡ÉÒÌÀ¡¢¿¹¡¡½¨Ëû¡¢°ËÆ£À¿Æó¡Ê2001¡Ë
    ÀÔ¿ñ¤Ë¤ª¤±¤ëÄˤߤÎÅÁ㵡¹½
    Î×Ëã¡¡Î×»þÁý´©¹æ299-310ÊÇ,¡Ê¿¿¶½¸ò°×¡Ë

Ê¿À®13ǯ¶ÈÀÓÌÜÏ¿°ìÍ÷¤ËÌá¤ë